[go: up one dir, main page]

AR104047A1 - Anticuerpos anti-ceacam6 y sus usos - Google Patents

Anticuerpos anti-ceacam6 y sus usos

Info

Publication number
AR104047A1
AR104047A1 ARP160100772A ARP160100772A AR104047A1 AR 104047 A1 AR104047 A1 AR 104047A1 AR P160100772 A ARP160100772 A AR P160100772A AR P160100772 A ARP160100772 A AR P160100772A AR 104047 A1 AR104047 A1 AR 104047A1
Authority
AR
Argentina
Prior art keywords
antigen
human
antibodies
ceacam6
nca
Prior art date
Application number
ARP160100772A
Other languages
English (en)
Inventor
Beckholve Philip
Holton Simon
Golfier Sven
Schlecker Eva
Maria - Bruder Jessica
Marius Glck Julian
Schnfeld Dorian
Dittmer Frank
Freiberg Christoph
Gritzan Uwe
Trautwein Mark
Willuda Jrg
Original Assignee
Bayer Pharma Aktiengellschaft
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengellschaft, Deutsches Krebsforsch filed Critical Bayer Pharma Aktiengellschaft
Publication of AR104047A1 publication Critical patent/AR104047A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Regiones de unión al antígeno y anticuerpos recombinantes y fragmentos funcionales que contienen aquellas regiones de unión al antígeno que sean específicas de la CEACAM6 (molécula de adhesión celular relacionada con el antígeno carcinoembrionario 6, CD66c, antígeno no específico de reacción cruzada, NCA, NCA-50/90) humana y de Macaca fascicularis, y que no presentan una reacción cruzada significativa con la CEACAM1 humana, la CEACAM3 humana y la CEACAM5 humana más estrechamente relacionadas. Provee además métodos para generar este tipo de anticuerpos. Por lo tanto, los anticuerpos se pueden usar para tratar el cáncer y otros trastornos y condiciones asociadas con la expresión de la CEACAM6. También provee secuencias de ácidos nucleicos que codifican los anticuerpos precedentes, vectores que contienen los mismos, composiciones farmacéuticas y conjuntos de elementos con instrucciones para su uso.
ARP160100772A 2015-03-23 2016-03-22 Anticuerpos anti-ceacam6 y sus usos AR104047A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15160292 2015-03-23

Publications (1)

Publication Number Publication Date
AR104047A1 true AR104047A1 (es) 2017-06-21

Family

ID=52692556

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100772A AR104047A1 (es) 2015-03-23 2016-03-22 Anticuerpos anti-ceacam6 y sus usos

Country Status (27)

Country Link
US (3) US10584167B2 (es)
EP (2) EP3628688A1 (es)
JP (2) JP6815329B2 (es)
KR (1) KR102749339B1 (es)
CN (1) CN107743495B (es)
AR (1) AR104047A1 (es)
AU (1) AU2016236270B2 (es)
BR (1) BR112017020373A2 (es)
CA (1) CA2980390A1 (es)
CY (1) CY1122627T1 (es)
DK (1) DK3274370T3 (es)
ES (1) ES2768784T3 (es)
HR (1) HRP20192280T1 (es)
HU (1) HUE048111T2 (es)
IL (1) IL254534B (es)
LT (1) LT3274370T (es)
MX (1) MX376973B (es)
PE (1) PE20171790A1 (es)
PL (1) PL3274370T3 (es)
PT (1) PT3274370T (es)
RS (1) RS59878B1 (es)
RU (1) RU2739163C2 (es)
SG (1) SG11201707800QA (es)
SI (1) SI3274370T1 (es)
TW (1) TWI719969B (es)
WO (1) WO2016150899A2 (es)
ZA (1) ZA201707138B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3274370T3 (da) 2015-03-23 2020-02-17 Bayer Pharma AG Anti-ceacam6-antistoffer og anvendelser deraf
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
SG11201903178QA (en) * 2016-10-10 2019-05-30 Singhealth Services Pte Ltd Anti-ceacam6 antibodies and methods of use
JP2019535319A (ja) * 2016-11-14 2019-12-12 ダイノナＤｉｎｏｎａ ＣＤ６６ｃに特異的に結合する抗体およびその用途
KR102014400B1 (ko) * 2017-01-05 2019-08-28 한국생명공학연구원 Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체
US11623953B2 (en) 2017-02-27 2023-04-11 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
WO2018200562A1 (en) * 2017-04-24 2018-11-01 Memorial Sloan Kettering Cancer Center Anti-cd33 antibody agents
US20200140572A1 (en) * 2017-05-23 2020-05-07 Kaohsiung Medical University Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy
US11708418B2 (en) * 2017-08-10 2023-07-25 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain
KR102134954B1 (ko) 2018-01-08 2020-07-16 충북대학교 산학협력단 CEACAM6 발현 억제를 위한 siRNA 및 이를 포함하는 선암 치료제
WO2019160970A1 (en) * 2018-02-13 2019-08-22 Precision Biologics, Inc. Methods and compositions for targeting treg cells
SG11202008784RA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
JP7489922B2 (ja) * 2018-05-23 2024-05-24 ベイジーン リミテッド 抗ｏｘ４０抗体及び使用方法
US11555071B2 (en) * 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7621943B2 (ja) * 2018-11-14 2025-01-27 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
CN113164778B (zh) * 2018-12-19 2024-07-26 拜耳公司 抗ceacam6和tim3抗体的药物组合
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020244528A1 (zh) * 2019-06-04 2020-12-10 上海吉倍生物技术有限公司 一种抗ceacam5的单克隆抗体及其制备方法和用途
WO2021050799A1 (en) * 2019-09-13 2021-03-18 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
WO2021178951A1 (en) * 2020-03-06 2021-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor targeted fluorescence guidance for intraoperative margin assessment
CN111533808B (zh) * 2020-03-10 2021-02-09 南京医科大学 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
CN112457402B (zh) * 2020-10-21 2022-08-30 北京纽安博生物技术有限公司 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用
WO2022116079A1 (zh) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 一种抗ceacam5的人源化抗体及其制备方法和用途
JP2023554554A (ja) * 2020-12-11 2023-12-27 マテリア セラピューティクス インコーポレイテッド チェックポイント阻害剤と組み合わせてボセンタンを使用するがんの処置
AU2021400975A1 (en) * 2020-12-18 2023-07-13 Bioardis, Llc Cea6 binding molecules and uses thereof
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
CN118043352A (zh) 2021-09-02 2024-05-14 德国癌症研究中心公共法律基金会 副作用减少的抗cecam6抗体
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
CN116196415B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 用于增敏pd-1抗体的混合制剂及其使用方法
CN121152803A (zh) * 2023-05-25 2025-12-16 百进公司 Ceacam6结合抗体和其抗原结合片段

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HRP20151102T1 (xx) 2005-07-01 2015-11-20 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
HRP20171653T1 (hr) 2009-11-24 2017-12-15 Medimmune Limited Vezna sredstva koja služe ciljano protiv b7-h1
US8404812B2 (en) 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
WO2011163401A2 (en) 2010-06-22 2011-12-29 Neogenix Oncology, Inc. Colon and pancreas cancer specific antigens and antibodies
CA2813133C (en) * 2010-10-01 2023-10-31 National Research Council Of Canada Anti-ceacam6 antibodies and uses thereof
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
US10131712B2 (en) 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
IL296026B2 (en) 2013-09-13 2024-10-01 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DK3274370T3 (da) * 2015-03-23 2020-02-17 Bayer Pharma AG Anti-ceacam6-antistoffer og anvendelser deraf
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
MA44659B1 (fr) 2016-04-12 2021-12-31 Symphogen As Anticorps anti-tim-3 et compositions
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
WO2018013818A2 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JP2019535319A (ja) 2016-11-14 2019-12-12 ダイノナＤｉｎｏｎａ ＣＤ６６ｃに特異的に結合する抗体およびその用途
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3

Also Published As

Publication number Publication date
IL254534A0 (en) 2017-11-30
AU2016236270A1 (en) 2017-10-12
CN107743495A (zh) 2018-02-27
PT3274370T (pt) 2020-01-30
US20180162940A1 (en) 2018-06-14
RS59878B1 (sr) 2020-03-31
US20200157214A1 (en) 2020-05-21
WO2016150899A2 (en) 2016-09-29
DK3274370T3 (da) 2020-02-17
SG11201707800QA (en) 2017-10-30
US10584167B2 (en) 2020-03-10
IL254534B (en) 2021-12-01
TWI719969B (zh) 2021-03-01
US11866495B2 (en) 2024-01-09
CA2980390A1 (en) 2016-09-29
US20200181261A1 (en) 2020-06-11
KR102749339B1 (ko) 2025-01-03
RU2739163C2 (ru) 2020-12-21
HUE048111T2 (hu) 2020-05-28
EP3274370B1 (en) 2019-11-20
LT3274370T (lt) 2020-02-10
JP2018510636A (ja) 2018-04-19
JP2021058199A (ja) 2021-04-15
US11773164B2 (en) 2023-10-03
CN107743495B (zh) 2021-05-14
KR20170128567A (ko) 2017-11-22
MX376973B (es) 2025-03-07
SI3274370T1 (sl) 2020-02-28
BR112017020373A2 (pt) 2018-06-05
EP3628688A1 (en) 2020-04-01
HK1246312A1 (zh) 2018-09-07
ZA201707138B (en) 2022-11-30
PL3274370T3 (pl) 2020-05-18
JP6815329B2 (ja) 2021-01-20
TW201713693A (zh) 2017-04-16
RU2017137010A3 (es) 2019-12-12
MX2017012278A (es) 2018-05-23
EP3274370A2 (en) 2018-01-31
CY1122627T1 (el) 2021-03-12
ES2768784T3 (es) 2020-06-23
HRP20192280T1 (hr) 2020-03-06
WO2016150899A3 (en) 2016-11-17
JP7185379B2 (ja) 2022-12-07
PE20171790A1 (es) 2017-12-28
RU2017137010A (ru) 2019-04-23
AU2016236270B2 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
AR104047A1 (es) Anticuerpos anti-ceacam6 y sus usos
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
AR110676A1 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
CO2020000357A2 (es) Receptores de células t novedosos, e inmunoterapia usando los mismos
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
PE20190120A1 (es) Moleculas de union a bcma y metodos de uso de las mismas
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
ECSP22015276A (es) Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
MX2025012685A (es) Anticuerpos para claudin6 y metodos para tratar el cancer
EA201890294A1 (ru) Химерный полипептидный комплекс и способы его получения и применения
CL2016002689A1 (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
UY38432A (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
EA201991151A1 (ru) Новые т-клеточные рецепторы и иммунотерапия с их применением
AR112758A1 (es) Anticuerpos agonistas que unen cd137 humano, y usos de los mismos
ECSP16090450A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
AR101891A1 (es) Anticuerpos anti-vasa, y métodos de producción y uso de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal